BIIB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIIB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Biogen's earnings per share without non-recurring items for the three months ended in Sep. 2022 was $7.84. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2022 was $19.64.
During the past 12 months, Biogen's average earnings per share (NRI) Growth Rate was 92.20% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -21.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 0.40% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Biogen's EPS without NRI or its related term are showing as below:
During the past 13 years, Biogen's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 205.20% per year. The lowest was -66.00% per year. And the median was 26.65% per year.
Biogen's EPS (Diluted) for the three months ended in Sep. 2022 was $7.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $19.64.
Biogen's EPS (Basic) for the three months ended in Sep. 2022 was $7.86. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $19.68.
The historical data trend for Biogen's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Biogen's EPS without NRI, along with its competitors' market caps and EPS without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Biogen's EPS without NRI distribution charts can be found below:
* The bar in red indicates where Biogen's EPS without NRI falls in comparison to its industry or sector. The grey bar indicates the EPS without NRI's extreme value range as defined by GuruFocus.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.
EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (NAS:BIIB) EPS without NRI Explanation
A Non Operating Income refers to an entry that appears on a company's financial statements that is unlikely to happen again. It represents a one-time expense involving an unpredictable event and is not part of a firm's normal, day-to-day operations.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Biogen's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Viehbacher | director, officer: President and CEO | C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Nicole Murphy | officer: Head of Pharm Ops and Tech | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Rachid Izzar | officer: Head of Alzheimer's Disease | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Jones William D /ca/ | director | |
Maria C Freire | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
Michael R Mcdonnell | officer: EVP, Chief Financial Officer | C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810 |
Alphonse Galdes | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
William A Hawkins | director | MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604 |
Jesus B Mantas | director | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Robin Kramer | officer: VP, Chief Accounting Officer | 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109 |
Daniel Karp | officer: EVP, Corporate Development | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Jeffrey D Capello | officer: EVP & Chief Financial Officer | C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912 |
Chirfi Guindo | officer: EVP Glob. Mkt Acc & Cust Innov | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Ginger Gregory | officer: EVP, Human Resources | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Jean-paul Kress | officer: EVP Pres Int'l & Global Hd GTO | 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire 01-27-2023
By PRNewswire 01-16-2023
By GlobeNewswire 01-27-2023
By Value_Insider 11-28-2022
Other Sources
By tipranks.com 2023-01-22
By Yahoo Finance 2023-01-24
By Zacks 2023-01-26
By Reuters 2023-01-26
By Zacks 2023-01-23
By CNBC 2023-01-20
By Yahoo Finance 2023-01-25
By Yahoo Finance 2023-01-20
By Bloomberg 2023-01-25
By Zacks 2023-01-24
By Zacks 2023-01-30
By Reuters 2023-01-29
By Yahoo Finance 2023-01-20
By Yahoo Finance 2023-01-26
By Yahoo Finance 2023-01-20
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.